JP2017508469A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508469A5
JP2017508469A5 JP2016556734A JP2016556734A JP2017508469A5 JP 2017508469 A5 JP2017508469 A5 JP 2017508469A5 JP 2016556734 A JP2016556734 A JP 2016556734A JP 2016556734 A JP2016556734 A JP 2016556734A JP 2017508469 A5 JP2017508469 A5 JP 2017508469A5
Authority
JP
Japan
Prior art keywords
metagene
cancer
genes
metagenes
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050096 external-priority patent/WO2015135035A2/en
Publication of JP2017508469A publication Critical patent/JP2017508469A/ja
Publication of JP2017508469A5 publication Critical patent/JP2017508469A5/ja
Pending legal-status Critical Current

Links

JP2016556734A 2014-03-11 2015-03-11 癌悪性度、予後及び治療に対する反応性の決定 Pending JP2017508469A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014900813 2014-03-11
AU2014900813A AU2014900813A0 (en) 2014-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014901212 2014-04-03
AU2014901212A AU2014901212A0 (en) 2014-04-03 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014904716 2014-11-21
AU2014904716A AU2014904716A0 (en) 2014-11-21 Determining cancer agressiveness, prognosis and responsiveness to treatment
PCT/AU2015/050096 WO2015135035A2 (en) 2014-03-11 2015-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment

Publications (2)

Publication Number Publication Date
JP2017508469A JP2017508469A (ja) 2017-03-30
JP2017508469A5 true JP2017508469A5 (https=) 2018-03-29

Family

ID=54072534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556734A Pending JP2017508469A (ja) 2014-03-11 2015-03-11 癌悪性度、予後及び治療に対する反応性の決定

Country Status (11)

Country Link
US (1) US20170107577A1 (https=)
EP (1) EP3119908A4 (https=)
JP (1) JP2017508469A (https=)
KR (1) KR20160132067A (https=)
CN (1) CN106661614A (https=)
AU (1) AU2015230677A1 (https=)
BR (1) BR112016020897A2 (https=)
CA (1) CA2941769A1 (https=)
MX (1) MX2016011612A (https=)
SG (2) SG10201807838SA (https=)
WO (1) WO2015135035A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CA2947624A1 (en) * 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2017085326A1 (en) * 2015-11-20 2017-05-26 Universite De Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
CA3044086A1 (en) * 2015-11-20 2017-05-26 Universite De Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
WO2017134000A1 (en) * 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN118108847A (zh) * 2016-08-07 2024-05-31 诺华股份有限公司 mRNA介导的免疫方法
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US11672801B2 (en) 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
WO2018152585A1 (en) * 2017-02-23 2018-08-30 The Council Of The Queensland Institute Of Medical Research "biomarkers for diagnosing conditions"
WO2018161081A1 (en) * 2017-03-03 2018-09-07 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
KR20190133038A (ko) * 2017-03-28 2019-11-29 난토믹스, 엘엘씨 PARADIGM을 이용한 유방암에서의 miRNA 유도 침묵 모델링(MODELING miRNA INDUCED SILENCING IN BREAST CANCER WITH PARADIGM)
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
US10854338B2 (en) * 2017-03-29 2020-12-01 Imaging Endpoints II LLC Predicting breast cancer responsiveness to hormone treatment using quantitative textural analysis
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
WO2018183921A1 (en) * 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
GB202209539D0 (en) * 2017-06-13 2022-08-10 Bostongene Corp Systems and methods for identifying cancer treatments from normalized biomarker scores
EP3641745A1 (en) * 2017-06-20 2020-04-29 The Institute of Cancer Research : The Royal Cancer Hospital Methods and medical uses
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
AU2018300007A1 (en) 2017-07-10 2020-02-27 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
CN107868825A (zh) * 2017-11-21 2018-04-03 山东省千佛山医院 一种诊治肺腺癌的分子标记物
WO2019173456A1 (en) * 2018-03-06 2019-09-12 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
EP4552696A3 (en) * 2018-05-15 2025-11-05 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN108704135A (zh) * 2018-05-24 2018-10-26 江苏大学附属医院 Chaf1a抑制剂在制备胃癌治疗药物中的用途
CN108866189B (zh) * 2018-07-12 2022-03-01 吉林大学 一种喉鳞状细胞癌易感性预测试剂盒及系统
CN108841959B (zh) * 2018-07-12 2022-03-01 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN108949984B (zh) * 2018-07-25 2022-01-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 基因desi2在三阴乳腺癌诊断、预后评估及治疗中的应用
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN110787296B (zh) * 2018-08-01 2024-04-16 复旦大学附属肿瘤医院 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer
CN110286219A (zh) * 2019-04-16 2019-09-27 福建师范大学 死亡相关蛋白激酶1在制备肾透明细胞癌术后预后评估试剂盒中的应用
CN111370056B (zh) * 2019-05-22 2021-03-30 深圳思勤医疗科技有限公司 确定待测样本预定染色体不稳定指数的方法、系统和计算机可读介质
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
US11715565B2 (en) * 2019-11-08 2023-08-01 Tempus Labs, Inc. Evaluating effect of event on condition using propensity scoring
WO2021168200A1 (en) * 2020-02-19 2021-08-26 United States Government As Represented By The Department Of Veterans Affairs Identification of an egfr-bin3 pathway that actively suppresses invasion and reduces tumor size in glioblastoma
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
EP4181926A4 (en) * 2020-07-15 2024-08-21 Queensland University Of Technology DETERMINING THE RESPONSIVENESS OF A CANCER TO A TREATMENT
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
WO2022058427A1 (en) * 2020-09-16 2022-03-24 Novigenix Sa Biomarkers for immune checkpoint inhibitors treatment
CN112111575B (zh) * 2020-09-22 2023-01-10 重庆医科大学附属第一医院 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用
GB2628478A (en) 2020-10-29 2024-09-25 Ambergen Inc Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes
EP4247977A2 (en) * 2020-11-23 2023-09-27 Sanofi Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
AU2021410776A1 (en) * 2020-12-23 2023-05-04 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t cells
WO2022217060A1 (en) * 2021-04-09 2022-10-13 Cardiff Oncology, Inc. Cancer treatment using parp inhibitors and plk1 inhibitors
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
CN113355419B (zh) * 2021-06-28 2022-02-18 广州中医药大学(广州中医药研究院) 一种乳腺癌预后风险预测标志组合物及应用
CN113502329A (zh) * 2021-07-12 2021-10-15 隋雨桐 检测腺苷受体a2b表达量的试剂在制备肺腺癌的诊断和/或预后试剂盒中的应用
CA3240376A1 (en) * 2021-12-08 2023-06-15 Alexander MEVES Assessing and treating melanoma
CN114540500A (zh) * 2022-03-21 2022-05-27 深圳市陆为生物技术有限公司 评价乳腺癌患者整体生存的产品
CN115369173A (zh) * 2022-09-23 2022-11-22 河北医科大学第三医院 基因标志物组合在预测膀胱尿路上皮癌预后中的应用
EP4494152A4 (en) 2023-06-09 2025-10-08 Seekin Inc Shenzhen China METHODS FOR DETECTING CANCER
CN119913252A (zh) * 2023-10-31 2025-05-02 南京安吉生物科技有限公司 Gemin4基因及Gemin4蛋白在肿瘤中的应用
CN120290720B (zh) * 2025-04-11 2025-12-23 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120594831B (zh) * 2025-05-30 2026-03-13 南方医科大学南方医院 细胞外囊泡膜蛋白在制备早期胃癌诊断试剂盒中的应用
CN120536581B (zh) * 2025-06-19 2026-04-17 十堰市太和医院（湖北医药学院附属医院） Ul16结合蛋⽩2作为结直肠癌标志物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4679149B2 (ja) * 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 ヒト膵癌に関連する遺伝子およびポリペプチド
ES2504242T3 (es) * 2004-02-20 2014-10-08 Janssen Diagnostics, Llc Pronóstico de cáncer de mama
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
MX2009002535A (es) * 2006-09-05 2009-03-20 Veridex Llc Metodos para predecir la metastasis distante de cancer de mama primario negativo en el nodo linfatico, utilizando el analisis de expresion del gen de la trayectoria biologica.
NZ589143A (en) * 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
WO2010129965A1 (en) * 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes
WO2013169388A1 (en) * 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy

Similar Documents

Publication Publication Date Title
JP2017508469A5 (https=)
Wang et al. Circular RNA PVT1 promotes metastasis via miR-145 sponging in CRC
Wang et al. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer
Li et al. A seven immune-related lncRNAs model to increase the predicted value of lung adenocarcinoma
Feng et al. Exosomal miR-196a-1 promotes gastric cancer cell invasion and metastasis by targeting SFRP1
Hawsawi et al. BARD1 mystery: tumor suppressors are cancer susceptibility genes
Xu et al. Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: evidence from published literatures
Zhang et al. SNORA71A promotes colorectal cancer cell proliferation, migration, and invasion
Zhang et al. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group
Ahangari et al. A miRNA-binding site single nucleotide polymorphism in the 3′-UTR region of the NOD2 gene is associated with colorectal cancer
Vallina et al. Genes involved in the epithelial-mesenchymal transition in oral cancer: A systematic review
Liang et al. Identification and validation of a novel six-gene prognostic signature of stem cell characteristic in colon cancer
Lagmay et al. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor)
Chen et al. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets
Wang et al. Single-cell and spatial transcriptomic analysis reveals tumor cell heterogeneity and underlying molecular program in colorectal cancer
Chen et al. Integrative analysis of immune microenvironment-related CeRNA regulatory axis in gastric cancer
Zhu et al. A promising new cancer marker: Long noncoding RNA EGFR-AS1
Cao et al. A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients
Xie et al. Multi-omics identification of GPCR gene features in lung adenocarcinoma based on multiple machine learning combinations
Peng et al. Comprehensive landscape of m6A regulator-related gene patterns and tumor microenvironment infiltration characterization in gastric cancer
Wu et al. Impact of genetic variation in TLR4 3′ UTR on NSCLC genetic susceptibility
Zhang et al. Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer
Zhang et al. Subtype cluster analysis unveiled the correlation between m6A-and cuproptosis-related lncRNAs and the prognosis, immune microenvironment, and treatment sensitivity of esophageal cancer
Sun et al. Comprehensive analysis of lncRNA-mediated ceRNA network in papillary thyroid cancer.
Hu et al. An immune and epigenetics-related scoring model and drug candidate prediction for hepatic carcinogenesis via dynamic network biomarker analysis and connectivity mapping